FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 41 filers reported holding FUSION PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,058,553 | -44.3% | 1,560,982 | 0.0% | 1.62% | -32.6% |
| Q2 2023 | $7,289,786 | +23.9% | 1,560,982 | 0.0% | 2.40% | -0.8% |
| Q1 2023 | $5,884,902 | +19.7% | 1,560,982 | -0.0% | 2.42% | +13.3% |
| Q4 2022 | $4,917,100 | +4.6% | 1,560,984 | 0.0% | 2.14% | +24.5% |
| Q3 2022 | $4,699,000 | +20.9% | 1,560,984 | +0.0% | 1.72% | -12.3% |
| Q2 2022 | $3,887,000 | -68.7% | 1,560,982 | -2.3% | 1.96% | -66.7% |
| Q1 2022 | $12,419,000 | +90.8% | 1,598,377 | 0.0% | 5.88% | +115.9% |
| Q4 2021 | $6,509,000 | -48.6% | 1,598,377 | -0.0% | 2.72% | -39.2% |
| Q3 2021 | $12,659,000 | +0.4% | 1,598,379 | +0.0% | 4.47% | -10.0% |
| Q2 2021 | $12,613,000 | -26.4% | 1,598,377 | -0.0% | 4.97% | -9.6% |
| Q1 2021 | $17,135,000 | -8.8% | 1,598,379 | 0.0% | 5.50% | -11.2% |
| Q4 2020 | $18,781,000 | – | 1,598,379 | – | 6.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,598,379 | $12,659,000 | 4.47% |
| ADAMS STREET PARTNERS LLC | 2,947,809 | $23,347,000 | 3.00% |
| JOHNSON & JOHNSON | 3,670,516 | $29,070,000 | 2.55% |
| Sio Capital Management, LLC | 259,763 | $2,057,000 | 0.66% |
| Orbimed Advisors | 3,224,770 | $25,540,000 | 0.28% |
| TPG Group Holdings (SBS) Advisors, Inc. | 2,551,794 | $20,210,000 | 0.20% |
| Rock Springs Capital Management LP | 948,327 | $7,511,000 | 0.16% |
| Perceptive Advisors | 1,254,607 | $9,936,000 | 0.14% |
| AlphaCentric Advisors LLC | 71,500 | $566,000 | 0.14% |
| Artal Group S.A. | 750,000 | $5,940,000 | 0.13% |